Setmelanotide injection, as a highly targeted regulatory substance, focuses on specific congenital metabolic abnormalities and is not widely applicable to various metabolic disorders. Compared to conventional metabolic regulatory substances, its application scenarios exhibit distinct specificity and lack broad-spectrum adaptability. Instead, it precisely anchors the imbalance of body fat metabolism induced by congenital gene sequence deviations, while also covering the mild bodily reactions that may accompany such regulatory processes. This specificity allows it to avoid the limitations of conventional regulatory methods and specifically target metabolic abnormalities caused by congenital genetic factors, without involving any related disorders caused by acquired factors. Its core application orientation always revolves around the body fat metabolism disorders and their derivative mild reactions mediated by congenital genetic deviations.
Our Products Overview
Setmelanotide COA
 |
||
| Certificate of Analysis | ||
| Compound name | Setmelanotide | |
| Grade | Pharmaceutical grade | |
| CAS No. | 1294000-61-5 | |
| Quantity | 39g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090033 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |  |
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage |
Store in a sealed, dark, and dry place below -20°C |
|
 |
||
|
|
||
| Chemical Formula | C49H68N18O9S2 |
| Exact Mass | 1116.49 |
| Molecular Weight | 1117.32 |
| m/z | 1116.49 (100.0%), 1117.49 (53.0%), 1118.49 (13.8%), 1118.48 (9.0%), 1117.48 (6.6%), 1119.48 (4.8%), 1118.49 (3.5%), 1118.49 (1.8%), 1117.49 (1.6%), 1119.50 (1.5%), 1120.49 (1.2%) |
| Elemental Analysis | C, 52.67; H, 6.13; N, 22.57; O, 12.89; S, 5.74 |
Leren syndrome related body fat abnormalities and targeted regulation of semanolide
Lehren's syndrome belongs to a rare category of congenital inherited diseases. Its core cause is the sequence deviation of specific receptor genes, which leads to congenital imbalance of body fat metabolism mechanism, and then leads to abnormal retention of body fat and other related manifestations, which is essentially different from common acquired body fat disorder.
The core characteristics of special body fat abnormalities often gradually manifest in childhood, accompanied by progressive aggravation during growth and development. Body fat accumulation presents a specific distribution, with the trunk area as the main aggregation site, accompanied by synergistic manifestations such as delayed growth and development, low metabolic rate, etc. It is not simply an abnormality in body fat mass, but a local manifestation of gene mediated systemic metabolic imbalance.
The core pain point of such body fat abnormalities is that conventional intervention methods are difficult to address the fundamental causes at the genetic level, and can only temporarily alleviate surface symptoms without achieving long-term regulation.
The targeted regulatory effect of setmelanotide injection focuses on the core causes of this type of body fat abnormality, by precisely adapting relevant metabolic pathways to alleviate the disorder of body fat metabolism caused by genetic deviations. Its function logic is not to directly change the body fat stock, but to improve the metabolic imbalance caused by congenital gene defects by regulating the relevant signal transmission in the body, gradually correct the state of abnormal body fat retention, adapt to the special metabolic needs of patients with Lehren's syndrome, and provide targeted regulation direction for this rare body fat abnormality.
Relevant statistical data and cited documents are obtained from:
Diagnosis and Treatment Norms for Leren Syndrome (2020 Edition), Beijing Rare Disease Diagnosis and Treatment and Support Society, Rare Disease Diagnosis and Research, 2020
haws rm , gordon g , han jc , yanovski ja , yuan g , stewart mw . the efficacy and safety of setmelanotida in individuals with bardet - biedl syndrome or alstr öm syndrome : phase 3 trial design . contemp clin trials commun . 2021 jun ; 22 : 100780 .
Adaptation definition of severe early-onset body fat abnormalities mediated by congenital genetic defects
The application scope of setmelanotide injection has strict specificity and is only suitable for severe early-onset body fat abnormalities caused by congenital genetic defects. Its core definition criteria focus on the two core dimensions of "congenital genetic origin" and "early onset severity", excluding all body fat disorders caused by acquired factors.
The core impact of congenital genetic defects lies in the fact that congenital deviations in gene sequences directly disrupt the normal regulatory mechanism of body fat metabolism, leading to obstruction of body fat regulation signal transduction and subsequently causing abnormal accumulation of body fat. This type of genetic deviation is mostly innate, not caused by environmental or lifestyle factors, and has a certain genetic correlation. Some patients can be traced back to their family genetic history, and the root cause of their body fat disorder lies in irreversible deviations at the genetic level, rather than external factors that can be intervened after birth.
The core definition of early onset and severe onset specifically refers to symptoms of abnormal body fat that appear in childhood (mostly at the age of 6 and above) and gradually worsen with age, forming a distinct difference from body fat disorders caused by acquired factors in adulthood; In severe cases, the degree of abnormal retention of body fat is beyond the normal range, and with further impairment of metabolic function, if no targeted regulation is carried out, it may trigger a series of subsequent metabolic related chain reactions.
The exclusivity of the adaptation range clearly excludes body fat abnormalities caused by postnatal factors, whether it is dietary imbalance, metabolic rate decline, or other non genetic factors causing body fat accumulation, which are not within the adaptation range of semanolide. Its core value lies in providing targeted solutions for early-onset severe body fat abnormalities caused by congenital genetic defects.
Relevant statistical data and cited documents are obtained from:
Study on the Association between Congenital Genetic Defects and Early Onset Body Fat Abnormalities, Chinese Journal of Endocrinology and Metabolism, 2023
Minor adverse reactions related to injections
During the clinical application of setmelanotida, some users may experience mild adverse reactions, which are not universally present and exhibit distinct mild and reversible characteristics. The core focus is on the two dimensions of skin injection related discomfort and mild fluctuations in emotional rhythms, and there have been no serious adverse effects on the body's health. Compared with the obvious adverse reactions that may be caused by conventional intervention substances, the mild reactions of semanolide are mostly temporary adaptation reactions of the body to its action signals, without sustained damage, and do not require special intervention methods or adjuvant therapy. As the body gradually adapts to its mechanism of action, related discomfort symptoms will alleviate and disappear on their own, without hindering subsequent normal application. The overall impact on the body is at a relatively low level, and it will not interfere with the patient's daily life and basic metabolic status.
01.Skin injection related reactions
Mostly concentrated at the injection site, it presents as abnormal local skin sensation, such as slight redness, brief pain or slight swelling. The occurrence of such reactions is related to the injection method and individual skin tolerance, rather than serious adverse reactions of the drug itself. They usually disappear spontaneously within a short period of time after injection and do not affect subsequent normal use.
02.Emotional rhythm fluctuations
Manifested as brief emotional fluctuations, such as mild restlessness, low mood, or high mood, these fluctuations are mostly temporary and related to the slight impact of medication on signal transduction in the body. They do not form long-term emotional abnormalities, and as the body adapts to the medication, the related symptoms will gradually ease.
Relevant statistical data and cited documents are obtained from:
Clinical Characteristics Analysis of Body Fat Metabolism Abnormalities Mediated by Congenital Genetic Defects, Chinese Journal of Rare Diseases, 2022
chen ky , muniyappa r , abel bs , mullins kp , staker p , brychta rj , et al. ( april 2015 ). " rm - 493 , a melanocortin - 4 receptor ( mc 4 r ) agonist , increases resting energy expenditure in obese individuals " . the journal of clinical endocrinology and metabolism . 100 ( 4 ) : 1639 – 45 .
In summary, the core value of setmelanotide injection lies in the precise regulation of special body fat metabolism disorders caused by congenital genetic defects, and deep cultivation in the field of rare congenital metabolic abnormalities. It does not pursue broad-spectrum adaptation, but achieves targeted intervention. It is not only highly adapted to the imbalance of body fat metabolism associated with Leyen's syndrome, but also accurately covers severe early-onset body fat abnormalities mediated by congenital genetic defects, providing a pathway that is difficult to achieve with conventional interventions for this rare disease population. Adverse reactions such as skin injection discomfort and slight emotional fluctuations that may occur during application are temporary and reversible, and can be relieved on their own without special intervention. Overall, Simenotide has a clear range of adaptation and safety boundaries, avoiding body fat disorders caused by postnatal factors. It provides exclusive, precise, and safe regulatory directions for rare congenital body fat metabolism abnormalities, filling the gap in targeted interventions in this field.
References
Application of Simenotide in Rare Hereditary Body Fat Abnormalities, Chinese Journal of Medical Genetics, 2023
Clinical and Molecular Features of Patients With Leptin and Leptin Receptor Deficiency: Lessons of 25 Years of Research, Oxford Academic, 2023
Progress in clinical interventions for metabolic abnormalities associated with Leyen's syndrome, Chinese Journal of Practical Internal Medicine, 2022
Setmelanotida: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction, PMC, 2024
FAQ
Setmelanotida is a medication that acts on the melanocortin-4 receptor (MC4R) for the treatment of severe obesity caused by genetic disorders, including deficiency of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR).
Setmelanotida offers transformative efficacy in narrowly defined genetic subsets, whereas GLP-1 receptor agonists provide scalable benefits with systemic metabolic effects. Integration of molecular stratification with broad-spectrum pharmacotherapy may define the future architecture of precision obesity treatment.
Setmelanotida (Imcivree; Rhythm Pharmaceuticals) on Thursday became the first FDA-approved therapy to treat acquired hypothalamic obesity (HO), a rare disease caused by hypothalamic injury or function that leads to accelerated and sustained weight gain.
Hot Tags: setmelanotide injection, China setmelanotide injection manufacturers, suppliers
